Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
JAZZ

JAZZ - Jazz Pharmaceuticals PLC Stock Price, Fair Value and News

$165.40-2.45 (-1.46%)
Market Closed

43/100

JAZZ

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

43/100

JAZZ

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$152.51

Target 3M

$164.49

Target 6M

$160.44

JAZZ Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

JAZZ Price Action

Last 7 days

-2.2%

Last 30 days

-3.0%

Last 90 days

21.3%

Trailing 12 Months

33.9%

JAZZ RSI Chart

JAZZ Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

JAZZ Valuation

Market Cap

10.1B

Price/Earnings (Trailing)

-27.28

Price/Sales (Trailing)

2.42

EV/EBITDA

-19.74

Price/Free Cashflow

7.52

JAZZ Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$152.51

Target 3M

$164.49

Target 6M

$160.44

JAZZ Fundamentals

JAZZ Revenue

Revenue (TTM)

4.2B

Rev. Growth (Yr)

6.74%

Rev. Growth (Qtr)

7.69%

JAZZ Earnings

Earnings (TTM)

-368.5M

Earnings Growth (Yr)

16.91%

Earnings Growth (Qtr)

134.99%

JAZZ Profitability

EBT Margin

-16.91%

Return on Equity

-9.31%

Return on Assets

-3.24%

Free Cashflow Yield

13.3%

JAZZ Investor Care

Shares Dilution (1Y)

0.51%

Diluted EPS (TTM)

-6.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20254.1B4.1B4.2B0
20243.8B3.9B4.0B4.1B
20233.7B3.8B3.8B3.8B
20223.3B3.5B3.6B3.7B
20212.4B2.6B2.9B3.1B
20202.2B2.2B2.3B2.4B
20192.0B2.0B2.1B2.2B
20181.7B1.8B1.9B1.9B
20171.5B1.5B1.6B1.6B
20161.4B1.4B1.4B1.5B
20151.2B1.3B1.3B1.3B
2014923.1M1.0B1.1B1.2B
2013679.7M763.7M820.4M872.4M
2012323.9M383.6M485.8M586.0M
2011272.3M272.3M272.3M272.3M
2010000272.3M
Get all data in R, Python etc through our Historical Stock Data APIs

About Jazz Pharmaceuticals PLC

JAZZ
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
 CEO
 WEBSITEjazzpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES2800

Jazz Pharmaceuticals PLC Frequently Asked Questions

JAZZ is the stock ticker symbol of Jazz Pharmaceuticals PLC. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Jazz Pharmaceuticals PLC is 10.05 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check JAZZ's fair value in chart for subscribers.

The fair value guage provides a quick view whether JAZZ is over valued or under valued. Whether Jazz Pharmaceuticals PLC is cheap or expensive depends on the assumptions which impact Jazz Pharmaceuticals PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JAZZ.

As of Wed Jan 28 2026, JAZZ's PE ratio (Price to Earnings) is -27.28 and Price to Sales (PS) ratio is 2.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JAZZ PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Jazz Pharmaceuticals PLC has provided 0.025 (multiply by 100 for percentage) rate of return.